Caribou Biosciences, Inc. (CRBU)
0.2843
-0.03
(-8.44%)
USD |
NASDAQ |
Nov 20, 16:00
0.2843
0.00 (0.00%)
After-Hours: 20:00
Caribou Biosciences Net Income (Quarterly) : -26.61M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -26.61M |
| June 30, 2026 | -24.28M |
| March 31, 2026 | -25.08M |
| December 31, 2025 | -26.49M |
| September 30, 2025 | -27.55M |
| June 30, 2025 | -54.10M |
| March 31, 2025 | -39.99M |
| December 31, 2024 | -35.49M |
| September 30, 2024 | -34.68M |
| June 30, 2024 | -37.70M |
| March 31, 2024 | -41.23M |
| December 31, 2023 | -34.50M |
| September 30, 2023 | -10.00M |
| June 30, 2023 | -29.52M |
| Date | Value |
|---|---|
| March 31, 2023 | -28.04M |
| December 31, 2022 | -26.99M |
| September 30, 2022 | -26.65M |
| June 30, 2022 | -26.70M |
| March 31, 2022 | -19.09M |
| December 31, 2021 | -18.48M |
| September 30, 2021 | -20.97M |
| June 30, 2021 | -14.31M |
| March 31, 2021 | -13.16M |
| December 31, 2020 | -14.70M |
| September 30, 2020 | -7.933M |
| June 30, 2020 | -1.872M |
| March 31, 2020 | -9.80M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Anavex Life Sciences Corp. | 7.824M |
| Vaxcyte, Inc. | -297.06M |
| Foghorn Therapeutics, Inc. | 58.15M |
| Bolt Biotherapeutics, Inc. | -4.422M |
| Connect Biopharma Holdings Ltd. | -16.15M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.607M |
| Total Expenses (Quarterly) | 28.22M |
| EPS Diluted (Quarterly) | -0.2475 |
| Enterprise Value | -37.75M |
| Gross Profit Margin (Quarterly) | 63.29% |
| Profit Margin (Quarterly) | -1.66K% |
| Earnings Yield | -362.2% |
| Normalized Earnings Yield | -362.22 |